People having a stroke can receive clot-busting medication, providing they get it within 4.5 hours of the onset of symptoms.

Real-world data highlights how Viz Connect ® enhances care coordination and referral efficiency for cryptogenic stroke ...

President Donald Trump has nominated Dilworth Paxson partner John A. Squires to serve as the director of the US Patent and Trademark Office and under secretary of Commerce for intellectual property, ...

(European Heart Journal) After transcatheter patent foramen ovale (PFO) closure, patients with nickel hypersensitivity were more likely to develop device syndrome, but this did not translate into ...

such as the Amplatzer PFO Occluder and Gore® Cardioform Septal Occluder (GSO), are used for transcatheter patent foramen ovale (PFO) closure. However, the impact of nickel hypersensitivity on ...

Background: Patent foramen ovale (PFO) is among the most common congenital heart defects. Over the last two decades, the number of research publications on PFO has increased. This study aims to ...

It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022.

Merck has been tweaking Keytruda to make it easier to use—and to protect billions of dollars in revenue the company could lose after U.S. patent protection runs out in 2028 and rivals can begin ...

The Patent Trial and Appeal Board agreed with Pfizer and its German partner that Moderna's patents were invalid based on "prior art" that disclosed the inventions before Moderna patented them.

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Luckily, you have patented your new idea. And so, you take the patent violator to court and win. One would assume that such a victory would put an end to the theft. But that’s not how the legal ...